KDMN - Kadmon Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Kadmon Holdings Reports Positive Topline Results
Kadmon Holdings Inc. (KDMN) announced positive topline data from the pivotal trial of belumosudil (KD025). The trial was designed to evaluate the drug candidate in patients suffering from chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy. The study has already met the primary endpoint of Overall Response Rate at the interim analysis.
ROCKstar is the pivotal trial and the drug candidate achieved clinically meaningful and statistically significant Overall Response Rates of 73 percent with 200mg once a day dosage and